 |
Learning
Objectives
After completing this activity, participants should be better able to:
- Outline strategies for VTE risk assessment in medical and surgical cancer patients.
- Discuss guidelines issued by NCCN, ASCO, and the ACCP for VTE treatment and prevention in cancer patients.
- Describe the trials providing evidence used to create the guidelines.
- Formulate management plans for VTE treatment and prevention in cancer patients, including special patient populations with comorbidities (eg, obesity or renal impairment).
- Contribute to hospital policies by integrating evidence into practice to increase compliance with national measures on VTE prevention.
|
|
 |
|
Target Audience
This activity was planned to meet
the needs of pharmacists interested in
managing venous thromboembolism
Monday,
December 7, 2009
The Venetian
Venetian Ballroom C-D
Las Vegas, Nevada
Registration and Dinner: 6:30 PM - 7:00 PM
Scientific Program: 7:00 PM - 8:30 PM
|
|
| |
Faculty
Charles L. Bennett, MD, PhD, MPP
Professor of Medicine
Feinberg School of Medicine
Co-Director, Cancer Control Program
Robert H. Lurie Comprehensive
Cancer Center
Northwestern University
Chicago, Illinois
|
|
Edith A. Nutescu, PharmD, FCCP
Clinical Professor
Department of Pharmacy Practice &
Center for Pharmacoeconomic
Research
Director, Antithrombosis Center
University of Illinois at Chicago
College of Pharmacy & Medical Center
Chicago, Illinois
|
|
Ann K. Wittkowsky, PharmD, CACP
Clinical Professor
University of Washington School of
Pharmacy
Director, Anticoagulation Services
University of Washington Medical
Center
Seattle, Washington
|
Faculty Disclosures: All faculty and planners participating in continuing
education activities sponsored by Continuing Education Alliance are expected
to disclose to the audience any significant support or substantial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis. Complete disclosures will be provided at the time of the activity.
|
|
|
|
Program
Description
Each year, venous thromboembolism (VTE) affects an estimated 900,000
persons in the United States. About 20% of VTE cases occur in patients with
cancer. Cancer patients who develop VTE have a shorter life expectancy than
cancer patients without VTE or noncancer patients with VTE. There is a critical need to recognize cancer patients-risk of VTE and to initiate proper prophylaxis and treatment.
Although progress in the prevention and treatment of VTE has been made, underuse of thromboprophylaxis is common. VTE prophylaxis increasingly is incorporated into public reporting, guidelines, regulatory agency, and national quality initiative priorities. Practice guidelines have been issued by the American College of Chest Physicians (ACCP), the National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO). National regulatory agencies have established measures for VTE prophylaxis for hospital accreditation that require implementation of hospital policies for VTE prophylaxis using multidisciplinary teams. Pharmacists play a central role in the implementation of VTE prophylaxis processes in hospitals around the country as they seek to comply with these increased regulatory requirements.
Type of Activity
Knowledge
Goal
To familiarize pharmacists with the clinical burden of VTE in cancer patients,
the evidence base for VTE management and prevention in current practice
guidelines, and strategies for implementing VTE prophylaxis in clinical practice.
|
|
|
|
Registration and Dinner
6:30 pm - 7:00 pm
Scientific Agenda
7:00 pm - 7:10 pm
Welcome and Introduction
Edith A. Nutescu, PharmD, FCCP
7:10 pm - 7:30 pm
Clinical Burden of VTE and Risk Assessment in
Patients With Cancer
Charles L. Bennett, MD, PhD, MPP
7:30 pm - 7:50 pm
Guidelines for VTE Prevention and Treatment
Ann K. Wittkowsky, PharmD, CACP
7:50 pm - 8:10 pm
Strategies for Implementing VTE Guidelines and
Improving Care in Special Patient Populations
Edith A. Nutescu, PharmD, FCCP
8:10 pm - 8:20 pm
Question-and-Answer Session
Faculty Panel
8:20 pm - 8:30 pm
Closing Remarks
Edith A. Nutescu, PharmD, FCCP
To obtain CPE credit, participants must attend the full symposium, participate in the active learning exercises, complete the evaluation form, and return it to Continuing Education Alliance. CPE certificates will be sent via e-mail to participants within 6 weeks of the symposium date.
|
|
